WO2001079201A1 - Procede de preparation de derives de sulfanimide et cristaux de ceux-ci - Google Patents
Procede de preparation de derives de sulfanimide et cristaux de ceux-ci Download PDFInfo
- Publication number
- WO2001079201A1 WO2001079201A1 PCT/JP2001/003216 JP0103216W WO0179201A1 WO 2001079201 A1 WO2001079201 A1 WO 2001079201A1 JP 0103216 W JP0103216 W JP 0103216W WO 0179201 A1 WO0179201 A1 WO 0179201A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- represented
- formula
- solvent
- palladium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention ⁇ ⁇ - [[2- [ 5 - [[4- Mechirufuyuniru] Echiniru] thienyl]] sulfonyl] - methods and the crystal production of D_ tryptophan.
- an acetylene derivative and an acetylene derivative are force-coupled in a solvent such as dimethylformamide in the presence of copper iodide, a base, or a palladium catalyst.
- a solvent such as dimethylformamide
- the reaction in methane or palladium on carbon as a catalyst.
- the method described in J. Org. Chem. 1998, 8551-8553 can be mentioned.
- Examples of the bacterial head reaction performed in a water-containing system include the methods described in Tetrahedron Lett. 1996, 897-900 and Tetrahedron Lett. 1996, 5527-5530.
- reaction solvent is not a solvent having high mutual solubility with water, such as dimethylformamide, but is ethyl acetate, isopropyl acetate, isoptyl acetate, and normal acetate.
- a solvent having low mutual solubility with water such as acetic acid ester such as butyl or toluene or dichloromethane is preferable.
- Organic palladium catalysts containing phosphine ligands and the like commonly used in bacterial head reactions have high lipophilicity. If the reaction product has high lipophilicity, it is difficult to separate the product from the organic palladium catalyst. .
- the upper limit of the heavy metal concentration in the final drug substance is determined by the Japanese Pharmacopoeia, so the amount of residual palladium poses a major problem.
- the present invention relates to the following 2) to 21).
- the catalyst is palladium black, palladium carbon, bistriphenylphosphine chloride palladium (II), tetrax (triphenylphosphine) palladium (0) palladium oxide (11), palladium chloride (I ), Palladium bromide (11), And palladium acetate (II).
- New 1 has a main peak at 9 8 (degrees) "-.
- halogen means fluorine, chlorine, bromine, and iodine.
- FIG. 1 is a result of powder X-ray measurement of the A-type crystal obtained in Example 9.
- FIG. 2 is a result of powder X-ray measurement of the B-type crystal obtained in Example 11;
- FIG. 3 shows the result of powder X-ray measurement of the C-type crystal obtained in Example 12.
- This step is a step of coupling the starting material compound (IV) and the halogen-sulfonylated compound (V) using the Shotten-Baumann method.
- the compound (III) can be obtained by reacting and carrying out post-treatments usually performed.
- a mixed solvent of acetone and water is preferable.
- inorganic bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, potassium hydroxide, rubidium hydroxide, cesium hydroxide, and ammonium carbonate; and organic bases such as triethylamine, tributylamine, and diisoprovirethylamine. 3 amines are exemplified. Sodium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, triethylamine and the like are preferred.
- the compound (III) and p-tolylacetylene are cut using a bacterial head reaction. This is the step of pulling.
- Ethyl acid-water mixed solvent isopropyl acetate-aqueous mixed solvent, acetate ester-water mixed solvent such as isobutyl acetate-water mixed solvent, normal butyl acetate-water mixed solvent, etc., or tetrahydrofuran-aqueous mixed solvent, 1, 4 Mixed solvent of dioxane-water, mixed solvent of dimethoxetane-water, mixed solvent of toluene-water, N, N-dimethylformamide, N, N-dimethylacetamide, dimethylsulfoxide, tetrahydrofuran, dimethoxyethane, etc.
- acetate ester-water mixed solvent such as isobutyl acetate-water mixed solvent, normal butyl acetate-water mixed solvent, etc.
- tetrahydrofuran-aqueous mixed solvent 1, 4 Mixed solvent of dioxane-water, mixed solvent of dimethoxetane-water, mixed solvent of tol
- a solvent 0.001 equivalent to 0.5 equivalent, preferably 0.005 equivalent to 0.05 equivalent of cuprous salt, 1 equivalent to 10 equivalent, preferably 2 equivalent to 4 equivalent of In the presence of a base, and 0.001 to 0.5 equivalents, preferably 0.02 to 0.05 equivalents of the catalyst, 0.8 to 5 equivalents of the lig compound (III).
- 1 equivalent to 1.5 equivalents of trilua The reaction is carried out at 30 to 200 ° C., preferably at 50 to 80 ° C. for 1 to 30 hours, preferably 1.5 to 5 hours, and post-treatment is carried out as usual. Thereby, the compound (I ′) can be obtained.
- the reaction solution can be subjected to the following Step 3-A without performing post-treatment.
- a mixed solvent of ethyl sulphate and water is preferable.
- ethyl acetate: water 500: 1 to 1: 1 is preferred. More preferably, 100: 1 to 100: 10 is exemplified.
- Cuprous salts include copper fluoride, copper chloride, copper bromide, copper iodide, copper oxide, copper sulfide, copper selenide, copper acetate, copper cyanide, copper thiocyanate, and trifluoromethanesulfonate. Copper acid.
- copper chloride, copper bromide and copper iodide are mentioned.
- the base include tertiary amines such as triethylamine, triptylamine, trimethylamine, diisopropylmethylamine, diisopropylethylamine, dimethylaniline, and methyldibenzylamine. . Triethylamine, triptylamine, diisopropylethylamine and the like are preferred.
- the catalyst examples include palladium black, palladium carbon, palladium (II) chloride, palladium (II) chloride, bisbenzonitrile, palladium bromide (11), and palladium iodide.
- the solvent is particularly preferably dimethylformamide, dimethylacetamide, N-methylpyrrolidone, or N, N-hexamethylphosphamide.
- reaction used in this step can be carried out in a useful ethyl acetate solvent in an industrial production process, and that the reaction is accelerated by the presence of water in the system.
- the third step is a step of obtaining a compound (II) by the method described in the following step 3-A or step 3-B.
- compound (II) has a property that it is difficult to dissolve in both water and organic solvents, acetylene compounds, palladium catalysts, etc. existing in the organic layer after the acid treatment in the second step and copper salts and bases existing in the aqueous layer And other impurities can be easily removed.
- the reaction mixture is added to an acetate such as ethyl acetate, isopropyl acetate, isobutyl acetate, normal butyl acetate, or an extraction solvent such as dichloromethane, methyl isobutyl ketone, and hydrochloric acid, sulfuric acid, methanesulfonic acid, and phosphorus.
- an acetate such as ethyl acetate, isopropyl acetate, isobutyl acetate, normal butyl acetate, or an extraction solvent such as dichloromethane, methyl isobutyl ketone, and hydrochloric acid, sulfuric acid, methanesulfonic acid, and phosphorus.
- Add acid such as acid and nitric acid and, if necessary, saline solution to make the liquid acidic,
- An extract of I) is obtained.
- the extract is treated with activated carbon or the like, if necessary, and then alcohol and a basic substance are
- Ethyl acetate is preferred as the extraction solvent.
- Hydrochloric acid is preferred as the acid.
- ethanol examples include methanol, ethanol, n-pronanol, isopropanol, and n-butanol. Methanol is preferred.
- Examples of the basic substance include sodium hydroxide, sodium methoxide, rhodium hydroxide, ammonia, lithium hydroxide, cesium hydroxide, rubidium hydroxide, lithium methoxide, potassium methoxide, cesium methoxide, and sodium hydroxide. Tritium ethoxide, lithium ethoxide, potassium ethoxide, cesium ethoxide, lithium carbonate, lithium hydrogen carbonate, sodium carbonate, sodium hydrogen carbonate, lithium carbonate, potassium hydrogen carbonate, carbonate Rubidium, rubidium hydrogencarbonate, cesium carbonate, cesium hydrogencarbonate and the like. Sodium hydroxide or sodium methoxide is preferred.
- the compound (1 ') is dissolved in an organic solvent such as ethyl acetate, isopropyl acetate, isobutyl acetate, and normal butyl acetate, and the like, treated with activated carbon if necessary, and then methanol and a basic substance are added. Make the liquid alkaline. Seed crystals are added as necessary to obtain crystals of the precipitated compound (II).
- organic solvent such as ethyl acetate, isopropyl acetate, isobutyl acetate, and normal butyl acetate, and the like
- ethyl sulphate is preferred.
- Examples of the basic substance include sodium hydroxide, sodium methoxide, rhodium hydroxide, ammonia, lithium hydroxide, cesium hydroxide, rubidium hydroxide, lithium methoxide, potassium methoxide, cesium methoxide, and the like.
- Sodium hydroxide or sodium methoxide is preferred.
- This step is a step of obtaining compound (I) by treating compound (II) with an acid.
- Hydrochloric acid sulfuric acid in a solvent such as ethyl acetate-water mixed solvent, isopropyl acetate-aqueous mixed solvent, isobutyl acetate-water mixed solvent, normal butyl acetate-water mixed solvent, etc.
- the compound (I) can be obtained by adding an acid such as methanesulfonic acid, phosphoric acid, or nitric acid, making the liquid acidic, and performing a usual post-treatment.
- Seed crystals are added as necessary, and acetone-water mixed solvent, acetonitrile-monohydrate mixed solvent, methanol-water mixed solvent, ethyl acetate, ethyl acetate mixed solvent, tetrahydrofuran-water mixed solvent, Compound (I) can be obtained as a crystal from a solvent such as a mixed solvent of dimethylformamide water, a mixed solvent of dimethylacetamide water, and a mixed solvent of dimethyl sulfoxide water.
- a solvent such as a mixed solvent of dimethylformamide water, a mixed solvent of dimethylacetamide water, and a mixed solvent of dimethyl sulfoxide water.
- a mixed solvent of acetone and water is preferable.
- the compound (I) is dissolved in methanol or acetone, and the temperature is adjusted to 55 ° C, preferably 30 ° C. Water and, if necessary, seed crystals are added to the solution, and the mixture is stirred for 1 hour to 5 hours, preferably 1 hour to 2 hours, and the temperature is 0 ° C 55 ° C, preferably. Ku is was adjusted to 2 0 D C ⁇ 3 0 ° C , stirred for further 1 hour to 2 hours. The precipitated crystals are collected by filtration and dried to obtain Form A crystals.
- a methanol or acetone solution of the above compound (I) may be added to water which may contain seed crystals in the same manner.
- Compound (I) is dissolved in methanol, and the temperature is adjusted to 0 ° C to 30 ° C, preferably 15 ° C to 25 ° C. Add water and, if necessary, seed crystals to the solution, and at 0 ° C to 30 ° C, preferably 5 ° C to 20 ° C, for 0.1 hour to 2 hours, preferably 0.1 hour to 2 hours. Stir for 2 hours.
- the obtained monohydrate crystals are collected by filtration and dried under reduced pressure at 0 ° C to 100 ° C, preferably at 10 ° C to 50 ° C, to obtain Form B crystals.
- N substantially showing the X-ray powder diffraction pattern shown in 19).
- Compound (I) is dissolved in methanol, and the temperature is adjusted to 0 ° C to 30 ° C, preferably 15 ° C to 25 ° C. Add water and, if necessary, seed crystals to the solution, and at 0 ° C to 30 ° C, preferably 15 ° C to 25 ° C, for 0.1 hour to 2 hours, preferably 0.1 hour. Stir for ⁇ 0.2 hours. The resulting monohydrate crystals are collected by filtration and dried at atmospheric pressure at 0 ° C. to 50 ° C., preferably at 10 ° C. to 30 ° C., to obtain type C crystals.
- Compound (I) is dissolved in dimethyl sulfoxide.
- the solution is added to water at 0 ° C to 60 ° C, preferably 25 ° C to 45 ° C, and 10 ° C to 60 ° C, preferably 25 ° C.
- the mixture is stirred at C to 45 ° C for 0.1 to 2 hours, preferably for 0.1 to 0.5 hours.
- Stir. The solution is adjusted to 0 ° C. to 40 ° C., preferably 10 ° C. to 30 ° C., and stirred for 0.1 hour to 2 hours, preferably 0.1 hour to 0.5 hour.
- the precipitated crystals are collected by filtration. Then, it is dried under atmospheric pressure at 0 ° C. to 50 ° C., preferably at 10 ° C. to 30 ° C. to obtain a C-type crystal.
- reaction solution was added to a mixture of 41 mL of saline, 40 mL of ethyl acetate, and 3.8 g of hydrochloric acid, and after confirming the acidity of the pH, extracted into an organic layer, and washed with brine.
- activated carbon After treating the extract with activated carbon, add 13 mL of methanol and aqueous After confirming the lunarity, seed crystals were added for crystallization, and the crystals were collected by filtration and dried to obtain 9.9 g of compound (II-12) (9.0 g in terms of content). Total yield in terms of content from compound (IV) is 75%.
- III-l ⁇ -1 compound (III-1) 216 mg (purity about 97%), p-tolylacetylene 80 mg (0.69 mmol), 10% palladium (0) carbon 15.1 mg (0.03 eq), copper iodide 5 mg (0.05 eq), 1.1 mL of N, N-dimethylformamide (DMF) and 90 mg (1.8 eq) of triethylamine were added, and the mixture was heated to about 60 ° C and stirred for about 2 hours. After the reaction, the reaction solution was added to a mixture of saline, ethyl acetate and hydrochloric acid, and after confirming the acidity of the pH, extracted into an organic layer and washed with saline.
- the obtained diffraction pattern is shown in FIG. Example 11 Preparation of Compound (I) Form A Crystal
- FIG. 2 shows the obtained diffraction pattern.
- the compound (I) lg was dissolved in 2 mL of dimethyl sulfoxide (DMSO), and the solution was added dropwise to 20 mL of water at 45 ° C. over about 2 minutes. After stirring at 40 to 45 ° C for 30 minutes, the mixture was cooled to room temperature and further stirred for 1 hour. The crystals were collected by filtration and dried to obtain 0.99 g of monohydrate crystals of the compound (I). The process yield (in terms of content) was 95%. X-ray diffraction was measured under the same conditions as in Example 10.
- DMSO dimethyl sulfoxide
- Example 15 Compound (I) Preparation of A-type crystal from B-type or C-type crystal
- the B-type or C-type crystals of the compound (I) were stirred in methanol in water at room temperature for 4 hours to convert the B-type or C-type crystals into A-type crystals.
- Example 16 Compound (I) Preparation of A-type crystal from B-type crystal or C-type crystal
- Extract 30 is concentrated to g, further after concentration by addition of hexane 30 ml, hexane 25 ml, addition of seed crystals to the cooling crystallization to, and filtered dry compound, mp 4 0- 4 1 D C (V- 1) 23 g was obtained (dichloromethane may be used as the reaction and extraction solvent). 87% yield.
- Reference example 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001248766A AU2001248766A1 (en) | 2000-04-19 | 2001-04-16 | Process for preparation of sulfonamide derivatives and crystals thereof |
JP2001576800A JP3983546B2 (ja) | 2000-04-19 | 2001-04-16 | スルホンアミド誘導体の製造方法およびその結晶 |
EP01921842A EP1283210A4 (en) | 2000-04-19 | 2001-04-16 | PROCESS FOR THE PREPARATION OF SULFANIMIDE DERIVATIVES AND CRYSTALS THEREOF |
KR10-2005-7000371A KR20050008875A (ko) | 2000-04-19 | 2001-04-16 | 술폰아미드유도체의 제조방법 및 그의 결정 |
CA002406401A CA2406401A1 (en) | 2000-04-19 | 2001-04-16 | Process for preparation of sulfonamide derivatives and crystals thereof |
US10/257,752 US6831178B2 (en) | 2000-04-19 | 2001-04-16 | Process for preparation of sulfonamide derivatives and crystals thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000117562 | 2000-04-19 | ||
JP2000-117562 | 2000-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001079201A1 true WO2001079201A1 (fr) | 2001-10-25 |
Family
ID=18628863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/003216 WO2001079201A1 (fr) | 2000-04-19 | 2001-04-16 | Procede de preparation de derives de sulfanimide et cristaux de ceux-ci |
Country Status (8)
Country | Link |
---|---|
US (1) | US6831178B2 (ja) |
EP (1) | EP1283210A4 (ja) |
JP (1) | JP3983546B2 (ja) |
KR (2) | KR20050008875A (ja) |
CN (2) | CN1626533A (ja) |
AU (1) | AU2001248766A1 (ja) |
CA (1) | CA2406401A1 (ja) |
WO (1) | WO2001079201A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101006737B1 (ko) | 2008-03-17 | 2011-01-10 | 한국과학기술원 | 구리 촉매를 이용한 2-술포닐이미노인돌린 제조방법 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100746342B1 (ko) * | 2006-04-10 | 2007-08-03 | 한국과학기술원 | 구리 촉매 존재하에서 n―설포닐아미드 화합물의 제조방법 |
PT2144604E (pt) | 2007-02-28 | 2011-10-19 | Conatus Pharmaceuticals Inc | Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830 |
ES2575689T3 (es) * | 2008-12-23 | 2016-06-30 | Aquilus Pharmaceuticals, Inc | Compuestos y métodos para el tratamiento del dolor y otras enfermedades |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0652226A1 (en) * | 1993-11-04 | 1995-05-10 | Bristol-Myers Squibb Company | Process of preparing etoposide phosphate and etoposide |
US5629456A (en) * | 1993-12-10 | 1997-05-13 | Osaka Gas Company Limited | Method of preparing a fluorene derivative and the method of purifying thereof |
WO1997027174A1 (fr) * | 1996-01-23 | 1997-07-31 | Shionogi & Co., Ltd. | Derives d'acides amines sulfones et inhibiteurs de metalloproteinases contenant ces derives |
JPH11246527A (ja) * | 1998-03-02 | 1999-09-14 | Shionogi & Co Ltd | Mmp−8阻害剤 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ226171A (en) | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
US5702716A (en) * | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
WO1991001720A1 (en) | 1989-08-07 | 1991-02-21 | Herman Wade Schlameus | Composition and method of promoting hard tissue healing |
US5356629A (en) | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
CN1149088C (zh) | 1996-03-05 | 2004-05-12 | 奥奎斯特公司 | 骨生长促进组合物及其用途 |
JP2001501934A (ja) | 1996-09-30 | 2001-02-13 | チルドレンズ メディカル センター コーポレーション | 標的組織にリモデリングするよう有機マトリックスをプログラムするための方法及び組成物 |
US20020098222A1 (en) | 1997-03-13 | 2002-07-25 | John F. Wironen | Bone paste |
US6727266B2 (en) * | 2000-01-26 | 2004-04-27 | Shionogi & Co., Ltd. | Substituted tryptophan derivatives |
-
2001
- 2001-04-16 CA CA002406401A patent/CA2406401A1/en not_active Abandoned
- 2001-04-16 AU AU2001248766A patent/AU2001248766A1/en not_active Abandoned
- 2001-04-16 JP JP2001576800A patent/JP3983546B2/ja not_active Expired - Fee Related
- 2001-04-16 CN CNA2004100642419A patent/CN1626533A/zh active Pending
- 2001-04-16 KR KR10-2005-7000371A patent/KR20050008875A/ko not_active Application Discontinuation
- 2001-04-16 WO PCT/JP2001/003216 patent/WO2001079201A1/ja not_active Application Discontinuation
- 2001-04-16 EP EP01921842A patent/EP1283210A4/en not_active Withdrawn
- 2001-04-16 US US10/257,752 patent/US6831178B2/en not_active Expired - Fee Related
- 2001-04-16 CN CNB018112390A patent/CN1198821C/zh not_active Expired - Fee Related
- 2001-04-16 KR KR10-2002-7013970A patent/KR100496248B1/ko not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0652226A1 (en) * | 1993-11-04 | 1995-05-10 | Bristol-Myers Squibb Company | Process of preparing etoposide phosphate and etoposide |
US5629456A (en) * | 1993-12-10 | 1997-05-13 | Osaka Gas Company Limited | Method of preparing a fluorene derivative and the method of purifying thereof |
WO1997027174A1 (fr) * | 1996-01-23 | 1997-07-31 | Shionogi & Co., Ltd. | Derives d'acides amines sulfones et inhibiteurs de metalloproteinases contenant ces derives |
JPH11246527A (ja) * | 1998-03-02 | 1999-09-14 | Shionogi & Co Ltd | Mmp−8阻害剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1283210A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101006737B1 (ko) | 2008-03-17 | 2011-01-10 | 한국과학기술원 | 구리 촉매를 이용한 2-술포닐이미노인돌린 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
EP1283210A4 (en) | 2003-08-06 |
EP1283210A1 (en) | 2003-02-12 |
KR20020087496A (ko) | 2002-11-22 |
KR20050008875A (ko) | 2005-01-21 |
CN1436186A (zh) | 2003-08-13 |
US6831178B2 (en) | 2004-12-14 |
CA2406401A1 (en) | 2002-10-16 |
KR100496248B1 (ko) | 2005-06-17 |
CN1198821C (zh) | 2005-04-27 |
CN1626533A (zh) | 2005-06-15 |
JP3983546B2 (ja) | 2007-09-26 |
US20030187050A1 (en) | 2003-10-02 |
AU2001248766A1 (en) | 2001-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201912656A (zh) | 舒更葡糖鈉之製備方法及其晶型 | |
KR20190123607A (ko) | 피마살탄 트로메타민염 및 이를 포함하는 약제학적 조성물 | |
JP5640017B2 (ja) | イバブラジン硫酸塩及びそのi型結晶の製造方法 | |
WO2008125006A1 (fr) | Procédés de préparation du chlorhydrate d'ivabradine et de sa forme cristalline stable | |
WO2001079201A1 (fr) | Procede de preparation de derives de sulfanimide et cristaux de ceux-ci | |
JP4530287B2 (ja) | オキサセフェムの結晶 | |
US20070270586A1 (en) | Novel crystal of 7-[2-[(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) and method for preparation thereof | |
JP2014524438A (ja) | インデノピリジン誘導体 | |
JP5744017B2 (ja) | チエノピリミジン誘導体の結晶 | |
WO2015106717A1 (zh) | 哒嗪酮类衍生物及其制备方法和用途 | |
GB2421024A (en) | Cefdinir crystalline form C | |
JP6831496B2 (ja) | ベンゾオキサゾール誘導体の結晶 | |
JPWO2003055885A1 (ja) | 三環性トリアゾロベンゾアゼピン誘導体の新規結晶性物質 | |
WO2020009132A1 (ja) | ジアリールピリジン誘導体の製造方法 | |
CN112585126A (zh) | 四环化合物的制备方法 | |
KR20150079043A (ko) | 결정형 α 탈티레린의 제조방법 및 결정형의 변환방법 | |
JP5234856B2 (ja) | Npyy5受容体拮抗作用を有する化合物の結晶 | |
EP3565814B1 (en) | Process and crystalline forms of lumacaftor | |
JP4402361B2 (ja) | 塩酸エピナスチンの結晶多形 | |
JPWO2009119817A1 (ja) | 安定なヴィナミジニウム塩およびそれを用いた含窒素複素環合成 | |
JPH10152491A (ja) | 結晶性カルバペネム化合物 | |
KR102305091B1 (ko) | 라록시펜 염산염 신규 용매화물 및 이를 사용한 라록시펜 염산염 일수화물의 제조방법 | |
KR101158517B1 (ko) | 고 순도 피타바스타틴 칼슘염 결정형 a의 제조방법 | |
JP2010013356A (ja) | 結晶性カルバペネム化合物 | |
EP3565814A1 (en) | Process and crystalline forms of lumacaftor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 576800 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2406401 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10257752 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027013970 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001921842 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027013970 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018112390 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001921842 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020027013970 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001921842 Country of ref document: EP |